MTOR

[Nature Communications] Scientists showed that the deubiquitinase USP12 was commonly downregulated in the KrasG12D-driven mouse lung tumour and human non-small cell lung cancer owing to the activation of AKT-mTOR signalling.

[Mucosal Immunology] Using mice specifically defective for either mTORC1 or mTORC2 in ILC3s, scientists show that both mTOR complexes regulate the maintenance of type III Innate lymphoid cells at steady state and pathological immune response during colitis.

[Cell Reports] Researchers identified a human glioblastoma subset characterized by ERBB3 overexpression and nuclear accumulation.

[Cell Reports] Type 1 diabetes (T1D) patients had a lower serum MOTS-c level than did healthy controls. Furthermore, MOTS-c reduced T cell activation by alleviating T cells from the glycolytic stress in T1D patients, suggesting therapeutic potential.

[Oncogene] In vitro experiments showed that a subset of combination therapy melanoma cells was sensitive to mTORC1 inhibition.

[Journal of Cellular and Molecular Medicine] Investigators determined effects of LOC100996425 on human prostate cancer by targeting hepatocyte nuclear factor 4A via the AMPK/mTOR pathway.